Long story short, Ibalizumab has its purpose in the HIV world as a treatment for patients who have a multi drug resistance (MDR) problem. Because it has shown success against MDR, the FDA has granted it ODD, BTD, etc. Any MDR drug candidate, that shows potential for any indication (malaria, etc) is going to get the same treatment. The market for Ibalizumab is much smaller than pro-140 and the two drugs are really meant for different aspects of HIV. Additionally, Ibalizumab will never be a monotherapy and does not offer a reduction in side effects, allow if you are an MDR HIV patient, simply treating HIV will be enough to accept the side effects.
On the other hand, pro-140 has a very large market as it targets the R5 strain which makes up 67% of current U.S. HIV patients and 85% of all new U.S. Patients. I couldn't find statistics for the world, but I'm sure the market is there as well. The monotherapy is where pro-140 will make its money as you can get one subcutaneous shot a week (possibly twice or even once a month once full trial data is available) and side effects are literally not existent. I hate to use Charlie Sheen as an example, but he's been the only person to speak publicly about his experience on pro-140. I don't have his quotes, but his life has basically done a 180 degree turn since switching from the typical HAART regime to pro-140. No more headaches, stomach problems, etc. Pro-140 has been proven in a pivotal trial yet for monotherapy or combination therapy, but many patients have experienced success. 10 patients have had their viral loads suppressed for two years on monotherapy and that absolutely is not the result of a placebo effect. Yes, CYDY needs more cash, which mean dilution, and time to get pro-140 to market. Yes, Ibalizumab will get to the market first but that doesn't matter as they technically aren't competing for the same patients. And if somehow they do college for patients it seems a no brainier that patients would choose the once a week, sub cuts lies shot with zero side effects.
In conclusion, both Ibalizumab and pro-140 have their place among treatments for pro-140. But they cannot be compared directly. Pro-140 won't push Ibalizumab off the market and Ibalizumab won't keep pro-140 from taking its share of the HIV treatment market. I'm not here to state that pr0-140 will make any some a millionaire, but to give facts that pro-140 is not a flop, but a promising drug for those suffering from an HIV infection.
